Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Endothelial PDGF-CC regulates angiogenesis-dependent thermogenesis in beige fat

Seki T., Hosaka K., Lim S., Fischer C., Honek J., Yang Y.

Animal Study, published in Nat Commun (2016) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Nat Commun (2016)
Reported sample size
—
Source database
Europe PMC
PMID
27492130
PMCID
PMC4980448
DOI
10.1038/ncomms12152
Citations
87

Abstract (original English)

Cold- and β3-adrenoceptor agonist-induced sympathetic activation leads to angiogenesis and UCP1-dependent thermogenesis in mouse brown and white adipose tissues. Here we show that endothelial production of PDGF-CC during white adipose tissue (WAT) angiogenesis regulates WAT browning. We find that genetic deletion of endothelial VEGFR2, knockout of the Pdgf-c gene or pharmacological blockade of PDGFR-α impair the WAT-beige transition. We further show that PDGF-CC stimulation upregulates UCP1 expression and acquisition of a beige phenotype in differentiated mouse WAT-PDGFR-α(+) progenitor cells, as well as in human WAT-PDGFR-α(+) adipocytes, supporting the physiological relevance of our findings. Our data reveal a paracrine mechanism by which angiogenic endothelial cells modulate adipocyte metabolism, which may provide new targets for the treatment of obesity and related metabolic diseases.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Endothelial CellsAnimalsMice, Inbred C57BLMice, KnockoutHumansMice, ObeseDioxolesReceptor, Platelet-Derived Growth Factor alphaVascular Endothelial Growth Factor Receptor-2Vascular Endothelial Growth Factor A

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.